Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Onartuzumab in lung cancer: the fall of Icarus?
Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Rolfo C, et al. Among authors: cappuzzo f. Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30. Expert Rev Anticancer Ther. 2015. PMID: 25818471
cMET Exon 14 Skipping: From the Structure to the Clinic.
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. Van Der Steen N, et al. Among authors: cappuzzo f. J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. J Thorac Oncol. 2016. PMID: 27223456 Free article. Review.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Targeted therapy for NSCLC with driver mutations.
Minuti G, D'Incecco A, Cappuzzo F. Minuti G, et al. Among authors: cappuzzo f. Expert Opin Biol Ther. 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. Epub 2013 Aug 10. Expert Opin Biol Ther. 2013. PMID: 23930754 Review.
Pharmacotherapy targeting the EGFR oncogene in NSCLC.
Landi L, Cappuzzo F. Landi L, et al. Among authors: cappuzzo f. Expert Opin Pharmacother. 2014 Nov;15(16):2293-305. doi: 10.1517/14656566.2014.957179. Epub 2014 Sep 13. Expert Opin Pharmacother. 2014. PMID: 25219817 Review.
Management of NSCLC: focus on crizotinib.
Landi L, Cappuzzo F. Landi L, et al. Among authors: cappuzzo f. Expert Opin Pharmacother. 2014 Dec;15(17):2587-97. doi: 10.1517/14656566.2014.970174. Epub 2014 Oct 10. Expert Opin Pharmacother. 2014. PMID: 25301075 Review.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
309 results